Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age

• Egile Nagusiak: Parini R (Egilea), Pintos-Morell G (Egilea), Hennermann JB (Egilea), Hsu TR (Egilea), Karabul N (Egilea), Kalampoki V (Egilea), Gurevich A (Egilea), Ramaswami U (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2020-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Diso...